title: Seroprevalence of hepatitis and HIV infection among rural pregnant women in Cameroon.
abstract: Since some hepatitis viruses and the human immunodeficiency viruses share common modes of transmission, such as the sexual route, we undertook to investigate the prevalence of antibodies to these and other pathogens among 384 rural pregnant women. Our study was intended to form the basis of infection management policies in pregnancy. Antibodies and other markers of the hepatitis A, B, C, and D viruses (HAV, HBV, HCV, HDV), the human immunodeficiency virus type 1 (HIV-1) and Treponema pallidum were sought. We tested for antibodies to the viruses using the appropriate enzyme-linked immunosorbent assays. HCV and HIV-1 infection were confirmed using standard immunoblotting techniques. Regarding HBV, we tested for the surface antigen (HBsAg), antibody to the surface antigen (anti-HBs) and antibody to the core antigen (anti-HBc). A non-specific test, the rapid plasma reagin test (RPR), was used for estimating Treponema pallidum (syphilis) infection. We found an overall prevalence of antibodies to HAV of 91.4%, to HCV of 6.8%, to HDV of 0%, and to HIV-1 of 3.5%. We found no IgM antibodies to HAV. The incidence of HBV markers was as follows: 5.4% for HBsAg, 61.3% for anti-HBs, and 84.6% for anti-HBc. RPR reactivity was found in 15.8% of the women. These results will be used to establish appropriate management and preventative policies for women attending the antenatal clinic. Prevention and appropriate early treatment of infections in these women will be considered.
authors.affiliation: Faculty of Medicine and Biomedical Sciences, University of Yaounde I. Cameroon.
authors.forename: P M
authors.initials: PM
authors.lastname: Ndumbe
authors.forename: J
authors.initials: J
authors.lastname: Skalsky
authors.forename: H I
authors.initials: HI
authors.lastname: Joller-Jemelka
mesh_terms: D000293:Adolescent; D000328:Adult; D002163:Cameroon / Q000453:epidemiology; D002648:Child; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000150:complications; D015528:HIV Seroprevalence; D015497:HIV-1 / Q000276:immunology*; D016174:Hepacivirus / Q000276:immunology; D035922:Hepatitis A Antibodies; D006508:Hepatitis Antibodies / Q000097:blood; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000097:blood / Q000276:immunology; D018937:Hepatitis C Antibodies; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000453:epidemiology*; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology*; D015995:Prevalence; D012424:Rural Population; D013587:Syphilis / Q000150:complications / Q000453:epidemiology; D013588:Syphilis Serodiagnosis
chemical_list: D035922:Hepatitis A Antibodies; D006508:Hepatitis Antibodies; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies